Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model

被引:2
|
作者
Folkeringa, R. J. [1 ]
Geven, L. M. [2 ]
Veldhuis, T. [2 ]
Hoogendoorn, M. [3 ]
Hofma, S. H. [1 ]
Van Roon, E. [4 ]
机构
[1] Med Ctr Leeuwarden, Dept Cardiol, NL-8934 AD Leeuwarden, Netherlands
[2] Thrombosis Serv Friesland Noord, NL-8934 AD Leeuwarden, Netherlands
[3] Med Ctr Leeuwarden, Dept Internal Med, NL-8934 AD Leeuwarden, Netherlands
[4] Med Ctr Leeuwarden, Dept Pharm, NL-8934 AD Leeuwarden, Netherlands
关键词
Atrial fibrillation; Novel oral anticoagulants; Anticoagulation; ATRIAL-FIBRILLATION; GUIDELINES; MANAGEMENT;
D O I
10.1007/s12471-014-0529-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This paper describes the implementation of novel oral anticoagulants (NOACs) through an anticoagulation nurse. Logistics and tasks of this new function are described and preliminary data are presented. Methods Indications for NOACs are explained by the treating cardiologists. Thereafter, the patient is referred to the anticoagulation nurse before starting a NOAC. After providing a patient with information and checking the creatinine clearance, co-medication and medical history, a prescription for NOAC is made. Results In 3 months, 51 patients were referred for NOAC therapy. Mean age was 68 years, CHA2DS2-VASc score was 2.9. Renal function was impaired in 28 %. Only 63 % of the patients had an uneventful start-up. NOAC therapy was withheld or prematurely stopped in 22 %. 30 % of patients needed a reduced NOAC dose. In 37 %, the anticoagulation nurse had extended patient contact, mainly because of (presumed) side effects. Conclusion Given the number of interactions that were made using a separate patient contact through the anticoagulation nurse, this seems to be an important improvement in the quality of care and deserves further expansion.
引用
收藏
页码:297 / 300
页数:4
相关论文
共 50 条
  • [31] Changes in anticoagulation practice in subjects admitted with stroke associated with atrial fibrillation, following introduction of direct oral anticoagulants over 2013-2021
    Harbison, Joseph
    McCormack, Joan
    Brych, Olga
    Collins, Ronan
    O'Connell, Niamh
    Randles, Mary
    Kennedy, Cormac
    Kelly, Peter J.
    Cassidy, Tim
    INTERNATIONAL JOURNAL OF STROKE, 2024, 19 (03) : 342 - 347
  • [32] Implementation of a comprehensive population management model to improve anticoagulation clinic efficiency of monitoring the safety and efficacy of direct oral anticoagulants (DOACs)
    Kibert, Jeffery, II
    Vinluan, Karen Joy
    Pardo, Kristyn
    Anderson, Mary
    Lucas, Jessica
    Parra, David
    Sipe, Amy
    Allen, Arthur
    Chia, Linda
    Spoutz, Patrick
    PHARMACOTHERAPY, 2017, 37 (12): : E216 - E217
  • [33] Anticoagulation treatment safety with vitamin K antagonists and novel oral anticoagulants within the registry of patients with non-valvular atrial fibrillation
    Sokolova, A. A.
    Anikina, O. S.
    Zhilenko, A. V.
    Belousov, S. R.
    Napalkov, D. A.
    Sulimov, V. A.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1113 - 1113
  • [34] Novel Oral Anticoagulants Versus Warfarin Therapy at Various Levels of Anticoagulation Control in Atrial Fibrillation-A Cost-Effectiveness Analysis
    You, Joyce H. S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2014, 29 (03) : 438 - 446
  • [35] Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding
    Mitrani, Lindsey R.
    De Los Santos, Jeffeny
    Driggin, Elissa
    Kogan, Rebecca
    Helmke, Stephen
    Goldsmith, Jeff
    Biviano, Angelo B.
    Maurer, Mathew S.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2021, 28 (01): : 30 - 34
  • [36] An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation
    Cardoso, Rhanderson
    Knijnik, Leonardo
    Bhonsale, Aditya
    Miller, Jared
    Nasi, Guilherme
    Rivera, Manuel
    Blumer, Vanessa
    Calkins, Hugh
    HEART RHYTHM, 2018, 15 (01) : 107 - 115
  • [37] Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation patients naive to oral anticoagulation and newly treated with novel oral anticoagulants
    Deitelzweig, S.
    Bruno, A.
    Tate, N.
    Ogbonnaya, A.
    Shah, M.
    Farrelly, E.
    Lokhandwala, T.
    Gupta, K.
    Eaddy, M.
    EUROPEAN HEART JOURNAL, 2015, 36 : 338 - 338
  • [38] Dementia and Stroke Rates Were Lower Among Patients Receiving Long-term Anticoagulation Therapy With Novel Oral Anticoagulants Compared to Warfarin
    Jacobs, Victoria
    May, Heidi T.
    Bair, Tami L.
    Anderson, Jeffrey L.
    Crandall, Brian G.
    Cutler, Michael
    Day, John D.
    Malender, Charles D.
    Osborn, Jeffrey S.
    Stevens, Scott M.
    Weiss, J. P.
    Woller, Scott C.
    Bunch, T. J.
    CIRCULATION, 2015, 132
  • [39] Elective Cardioversion in the Era of Novel Oral Anticoagulants - Does a Nurse Administered Verbal Questionnaire for Compliance Negate the Need for Routine Transoesophageal Echocardiography?
    Rowe, Matthew K.
    Lollback, Naomi
    Slater, Leanne
    Hill, John
    Gould, Paul A.
    Kaye, Gerald C.
    HEART LUNG AND CIRCULATION, 2018, 27 (08): : 989 - 994
  • [40] Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction
    Schwill, Simon
    Krug, Katja
    Peters-Klimm, Frank
    van Lieshout, Jan
    Laux, Gunter
    Szecsenyi, Joachim
    Wensing, Michel
    BMC FAMILY PRACTICE, 2018, 19